A Retrospective Single‐Center Study of Ferric Derisomaltose in Toddler and School‐Age Pediatric Patients

Several intravenous (IV) iron formulations are used in pediatrics for the treatment of iron deficiency anemia (IDA) and iron deficiency (ID). Ferric derisomaltose (FDI) is a formulation that has not been well studied. This study reports retrospective real-world use and response in young pediatric patients at a single tertiary hospital receiving IV FDI. A total of 11 FDI infusions were administered to pediatric patients ranging from 2 to 10 years of age with isolated ID or IDA. There were zero reactions. Results from our cohort suggest that FDI administration is feasible in this patient population.